<DOC>
	<DOCNO>NCT00002016</DOCNO>
	<brief_summary>To determine safety tolerance 3 dosage level human anti-cytomegalovirus ( CMV ) monoclonal antibody ( SDZ MSL-109 ) administer every 2 week total 8 dos maintenance phase ganciclovir ( DHPG ) therapy patient AIDS document evidence CMV retinitis . In addition patient positive CMV culture upon entry trial preliminary attempt make assess potential vivo antiviral effect concomitant administration DHPG SDZ MSL-109 .</brief_summary>
	<brief_title>A Phase I/II Trial Assess Safety Tolerance Escalating Doses Human Anti-Cytomegalovirus Monoclonal Antibody ( SDZ MSL-109 ) Patients With Acquired Immunodeficiency Syndrome CMV Retinitis</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Zidovudine ( AZT ) &lt; 600 mg/day . Experimental maintenance prophylactic therapy approve therapeutic agent nonviral opportunistic infection . Trimethoprim / sulfamethoxazole ( TMP / SMX ) . Pyrimethamine / sulfadoxine . Aerosolized pentamidine . Ketoconazole . Flucytosine ( 5FC ) . Antituberculosis therapy . Concurrent Treatment : Allowed : Maintenance phase ganciclovir ( DHPG ) therapy . Patients must : AIDS document ophthalmologic finding consistent cytomegalovirus ( CMV ) retinitis whose retinal lesion less 750 micron fovea visual symptom CMV retinitis . Completed treatment induction phase ganciclovir ( DHPG ) participate maintenance phase DHPG therapy . Expected survival = &gt; 6 month . Willingness ability give write informed consent . A copy sign witness consent form must maintain investigator 's study file . Seropositive presence circulate antiCMV immunoglobulin . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Significant pulmonary dysfunction . Uncontrolled unstable diabetes . Significant cardiovascular disease include uncontrolled hypertension , congestive heart failure , cardiac arrhythmia , angina pectoris , history myocardial infarction within one year entry study . Coagulation hemorrhagic disorder . Any active severe opportunistic infection . Concurrent Medication : Excluded : Therapy amphotericin B fluconazole . Any investigational drug . Biologicals include immunoglobulin therapy , granulocytemacrophagecolonystimulatingfactor ( GMCSF ) , erythropoietin alpha , interleukin . Patients follow excluded : Any significant organ system dysfunction describe Exclusion Coexisting Conditions . Any severe concomitant clinical condition . Prior Medication : Excluded within 2 week study entry : Therapy amphotericin B fluconazole . Any investigational drug . Biologicals include immunoglobulin therapy , granulocytemacrophagecolonystimulating factor ( GMCSF ) , erythropoietin alpha , interleukin . Excluded : Prior treatment monoclonal antibody derive animal specie . Prior Treatment : Excluded within 2 week study entry : Major surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1993</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Cytomegalovirus</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
</DOC>